Format

Send to

Choose Destination
Pulm Circ. 2013 Jan;3(1):156-9. doi: 10.4103/2045-8932.109961.

Developing treatments for pulmonary arterial hypertension.

Author information

1
Imperial College London, Hammersmith Campus, London, UK.

Abstract

Developing new treatments for pulmonary arterial hypertension (PAH) is a challenge. We have enjoyed success with regulatory approvals for three drug classes-prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. But we have also seen some disappointing results, for example, from studies with vasoactive intestinal polypeptide, statins and tergolide. Animal models are an unreliable predictor of efficacy in humans. The best model for the disease is the patient. This review discusses three major issues facing the evaluation of drugs in PAH patients-target validation, choosing the right dose, and early trial design.

KEYWORDS:

drug development; drug targets; early phase clinical trials; pulmonary hypertension

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center